Jessica F. Williams
No Rating Available
(Learn About Our Rating System)

Jessica F. Williams, MD, PhD

Languages spoken: English

  • Board Certification

    American Board of Pathology (Sub: Molecular Genetic Pathology)
    American Board of Pathology (Sub: Anatomic Path)

  • Board Certification and Academic Information

    Academic Departments Pathology -Assistant Professor (Clinical)
    Board Certification
    American Board of Pathology (Sub: Molecular Genetic Pathology)
    American Board of Pathology (Sub: Anatomic Path)

    Education history

    Undergraduate Major: Physics; Minor: Chemistry, Honors Program - University of Utah B.S.
    Professional Medical Medicine - Yale School of Medicine M.D.
    Graduate Training Molecular, Cellular, & Developmental Biology - Yale University M.S.
    Doctoral Training Cell Biology - Yale School of Medicine Ph.D.
    Residency Anatomic Pathology - Harvard Medical School, Brigham & Women's Hospital Resident
    Fellowship Molecular Genetic Pathology - University of Utah Spencer Fox Eccles School of Medicine, ARUP Laboratories Fellow
    Fellowship Genitourinary Pathology - Harvard Medical School, Brigham & Women's Hospital Fellow

    Selected Publications

    Journal Article

    1. Williams JF, Surovtsev IV, Schreiner SM, Chen Z, Raiymbek G, Nguyen H, Hu Y, Biteen JS, Mochrie SGJ, Ragunathan K, King M (2024). The condensation of HP1¿/Swi6 imparts nuclear stiffness. Cell reports, 43(7), 114373. (Read full publication)
    2. Williams JF, Lucas FM, Carrasco RD, Lovitch SB, Fisher DC, Kupper TS, Sadigh (2024). Primary cutaneous EBV+ extranodal NK/T-cell lymphoma of gamma/delta T-cell lineage in the posttransplantation setting. Journal of cutaneous pathology, (Read full publication)
    3. Bailey MLP, Surovtsev I, Williams JF, Yan H, Yuan T, Li K, Duseau K, Mochrie SGJ, King M (2023). Loops and the activity of loop extrusion factors constrain chromatin dynamics. Molecular biology of the cell, 34(8), ar78. (Read full publication)
    4. Williams JF, Vivero (2022). Diagnostic criteria and evolving molecular characterisation of pulmonary neuroendocrine carcinomas. Histopathology, 81(5), 556-568. (Read full publication)
    5. Williams JF, Zhao M, Najdawi F, Ahmadi S, Hornick JL, Wong KS, Barletta J (2022). Grading of Medullary Thyroid Carcinoma: an Interobserver Reproducibility Study. Endocrine pathology, 33(3), 371-377. (Read full publication)
    6. Yan H, Surovtsev I, Williams JF, Bailey MLP, King MC, Mochrie SG (2021). Extrusion of chromatin loops by a composite loop extrusion factor. Physical review. E, 104(2-1), 024414. (Read full publication)
    7. Bailey MLP, Yan H, Surovtsev I, Williams JF, King MC, Mochrie SG (2021). Covariance distributions in single particle tracking. Physical review. E, 103(3-1), 032405. (Read full publication)
    8. Hwang S, Williams JF, Kneissig M, Lioudyno M, Rivera I, Helguera P, Busciglio J, Storchova Z, King MC, Torres E (2019). Suppressing Aneuploidy-Associated Phenotypes Improves the Fitness of Trisomy 21 Cells. Cell reports, 29(8), 2473-2488.e5. (Read full publication)
    9. Hu Y, Bennett HW, Liu N, Moravec M, Williams JF, Azzalin CM, King M (2019). RNA-DNA Hybrids Support Recombination-Based Telomere Maintenance in Fission Yeast. Genetics, 213(2), 431-447. (Read full publication)
    10. Williams JF, Mochrie SGJ, King M (2019). A versatile image analysis platform for three-dimensional nuclear reconstruction. Methods (San Diego, Calif.), 157, 15-27. (Read full publication)
    11. Hu X, Liu ZZ, Chen X, Schulz VP, Kumar A, Hartman AA, Weinstein J, Johnston JF, Rodriguez EC, Eastman AE, Cheng J, Min L, Zhong M, Carroll C, Gallagher PG, Lu J, Schwartz M, King MC, Krause DS, Guo (2019). MKL1-actin pathway restricts chromatin accessibility and prevents mature pluripotency activation. Nature communications, 10(1), 1695. (Read full publication)
    12. Gebrael G, Sayegh N, Hage Chehade C, Jo Y, Narang A, Chigarira B, Tripathi N, Srivastava A, Tandar C, Williams JF, Garg D, Ji R, Maughan BL, Swami U, & Agarwal (2025). Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy. Prostate cancer and prostatic diseases,
    13. Alchoueiry M, Mansour H, Khabibullin D, Han T, Chaturantabut S, Bzeih W, Tang Y, Williams JF, Hirsch MS, Priolo C, Sellers WR, Henske E (2025). Targeting KIT With Antibody-Drug Conjugates in Chromophobe Renal Cell Carcinoma. Clinical genitourinary cancer, 23(4),
    14. Gandhi MM, Elkrief A, Moore CG, Ricciuti B, Alessi JV, Richards AL, Tischfield S, Williams J, Lamberti G, Pecci F, Di Federico A, Makarem M, Johnson BE, Nishino M, Sholl LM, Schoenfeld AJ, Awad M (2025). Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC. Journal of thoracic oncology, 20(6), 725-738.
    15. Yuan T, Yan H, Bailey MLP, Williams JF, Surovtsev I, King MC, Mochrie SG (2024). Effect of loops on the mean-squared displacement of Rouse-model chromatin. Physical review. E, 109(4-1), 044502.
    16. Williams JF, Glomski K, Ulbright TM, Hanley KZ, Iczkowski KA, Acosta AM, Nucci MR, Oliva E, Hirsch MS (2010). SOX2 Is the Most Sensitive Biomarker in Testicular and Gynecologic Embryonic-type Neuroectodermal Tumors (ENT) Based on a Comprehensive Evaluation of Biomarker Expression. The American journal of surgical pathology,